Freenome's Updated Colorectal Cancer Blood Test Delivers Major Performance Gains, Triggering $70M Abbott Milestone
PCSC is trading near its 52-week low of $10.13 (14% above the low).
Summary
Freenome's updated blood-based colorectal cancer screening test achieved best-in-class detection of precancerous lesions in a pivotal study, triggering a $70M milestone from partner Abbott and reinforcing the value proposition ahead of its SPAC merger with Perceptive Capital Solutions Corp.
Key Events · Product Development and Regulatory · PCSC
-
Updated Test Hits All Endpoints
The updated SimpleScreen CRC test met primary and secondary endpoints, showing 18.2% sensitivity for advanced precancerous lesions (APL) and 41.9% for APL with high-grade dysplasia—the highest reported for a non-invasive blood test in a pivotal study.
-
Significant Performance Improvement
Compared to the first-generation test, APL sensitivity improved from 13.7% to 18.2%, and HGD sensitivity from 30.5% to 41.9%. Modeling projects 9.5% fewer CRC cases and deaths per 100,000 screened.
-
$70M Abbott Milestone Triggered
The positive study outcome triggers a $70 million milestone payment from Abbott, contingent on FDA approval of the next-generation test and technology transfer, providing non-dilutive capital to the combined company.
-
Regulatory Path Forward
Freenome intends to submit a supplemental PMA to the FDA for the updated test. The first-generation test PMA is under review with a decision expected mid-2026.
Analysis · PCSC · Industrial Applications And Services
A significant leap in detecting advanced precancerous lesions—the key to preventing colorectal cancer—has been delivered by Freenome's updated SimpleScreen CRC blood test. Sensitivity for advanced precancerous lesions jumped to 18.2% from 13.7%, and for high-grade dysplasia to 41.9% from 30.5%, the highest reported for any non-invasive blood test in a pivotal study. Modeling translates this into 9.5% fewer cancer cases and deaths per 100,000 screened. These results also unlock a $70 million milestone payment from Abbott upon FDA approval of the next-generation test, strengthening the combined company's cash position ahead of the SPAC merger close. With the merger vote imminent and the S-4 already effective, this data de-risks the commercial thesis and validates the platform's competitive edge in the massive CRC screening market.
How filings like this one have moved
In the 30 days to Aug 23, 2026, 43.6% of the 999 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.10%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PCSC was trading at $11.56 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $117.6M. The 52-week trading range was $10.13 to $14.47. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.